Crohn's Disease and Colitis Trial, Recruiting NCT04926103 Sponsor: Hamilton Health Sciences Corporation Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT04926103
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People with active ulcerative colitis (UC), measured using a scoring system called the Mayo score, with a score above 3
  • People whose UC affects the lining of the bowel, confirmed by a score above 0 on the endoscopic part of the Mayo scoring system
  • Women who are able to become pregnant and are willing and able to use an acceptable form of contraception as outlined by Health Canada guidelines

Who may not be able to join:

  • People who are currently taking part in another clinical trial for UC
  • People who are unable to give informed consent
  • People with serious other medical conditions
  • People whose UC is severe enough to require a hospital stay
  • People whose UC medications have been increased or changed in the past 12 weeks (note: continuing stable doses of certain medications — such as 5-ASA, azathioprine, 6-mercaptopurine, or anti-TNF treatments like infliximab — may be permitted if the dose has been unchanged for at least 12 weeks; confirm with trial site)
  • People who have taken antibiotics in the last 30 days
  • People who are pregnant
  • People with significant liver problems at the time of screening, based on a specific liver enzyme (ALT) blood test result (confirm with trial site)
  • People with significant kidney problems at the time of screening, based on a specific kidney function blood test result (confirm with trial site)
  • People where, in the opinion of the trial doctor, participation could pose a health risk

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paul Moayyedi, MD, HHSC/McMaster

Phone: 9055212100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hamilton Health Sciences Corporation
Registry
ClinicalTrials.gov
Start date
1 July 2022
Est. completion
1 October 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Efficacy of FMT donors at inducing UC remission; Efficacy of FMT at maintaining remission in UC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov